Core Viewpoint - Starbucks is in the final negotiation stage for the sale of its China business, with private equity firms as the main candidates, aiming to retain a 30% stake for operational influence while selling 70% to multiple buyers [1][2]. Group 1: Sale Process and Candidates - The final candidates for the sale of Starbucks' China business include Boyu Capital, Carlyle Group, EQT, Sequoia China, and Primavera Capital, with the deal expected to be finalized by the end of October [1]. - Unlike previous rumors of involvement from corporate venture capital (CVC) firms like Tencent and JD.com, the final candidates are all private equity (PE) firms, which typically focus on enhancing operational efficiency and financial returns [1][2]. Group 2: Strategic Implications - Starbucks CEO Brian Niccol has indicated a desire to retain a significant equity stake, with plans to keep 30% of the shares, allowing for operational control while distributing the remaining 70% among several buyers [1][2]. - This structure enables Starbucks to maintain influence over its China operations and provides flexibility for future equity adjustments, such as potential buybacks when market conditions improve [2]. Group 3: Comparison with McDonald's - The case of McDonald's serves as a successful model for Starbucks, as McDonald's sold approximately 80% of its China business for $2.08 billion in 2017, leading to rapid expansion and improved profitability under local management [3]. - Following the introduction of local capital, McDonald's China opened 1,000 new stores in 2023 alone, demonstrating the potential benefits of local partnerships [3]. Group 4: PE Firms' Track Record - The private equity candidates have strong investment histories in the restaurant sector, such as Primavera Capital's previous investments in Yum China, which yielded significant returns [4]. - These firms are expected to help Starbucks adapt to market changes and enhance its digital capabilities while maintaining operational independence [5].

Core Viewpoint - Tianjin Development (00882) announced a partnership agreement involving its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical, to establish a fund with a total subscription amount of RMB 500 million (approximately HKD 547 million) [1] Group 1: Fund Structure and Investment Focus - The fund will primarily invest in equity of unlisted companies and/or stocks issued or traded in a non-public manner by listed companies, focusing on the health and biotechnology sectors in China, including innovative drugs, medical devices, and related services [1] - Lifescience Pharmaceutical has committed RMB 174 million (approximately HKD 190 million), representing 34.75% of the total subscription amount for the fund [1] Group 2: Risk Management and Investment Strategy - By participating in the fund, Lifescience Pharmaceutical's cost risk is limited to its subscribed amount, avoiding additional expenses and debts compared to direct investments [2] - The fund's investment decisions require approval from the investment decision committee, ensuring that decisions are made with the consent of both Jianxin Equity and Teda Private Equity [2] Group 3: Strategic Benefits and Long-term Outlook - Participation in the fund will enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [3] - The investment is expected to provide opportunities for mergers and acquisitions aligned with the company's strategic goals, improve capital allocation efficiency, and enhance the company's sustainable operational capabilities [3]